[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-cancer":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,62,75,103,128,155,182,213,241,266,289,322,352,387,414,436,465,503,527],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":38,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100053414","phase-1-autologous-t-cells-transduced-with-retroviral-vectors-expressing-tcrs-for-participant-specific-neoantigens-in-patients-with-hematologic-malignancies-100053414",false,"NCT06904066","Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies","A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies","* INCLUSION CRITERIA:\n\nMalignancy diagnosis requirements:\n\n-Eligible diagnoses include AML (acute myeloid leukemia), MDS (myelodysplastic syndrome), CMML(chronic myelomonocytic leukemia), CML (chronic myeloid leukemia), and T-ALL (T-acute lymphoblastic leukemia\u002Flymphoma) meeting standard diagnostic criteria as described in the 5th edition World Health Organization Classification of Hematologic Tumors and\u002For the International Consensus Classification of Myeloid Neoplasms and Acute Leukemias. Multiple myeloma participants meeting International Working Group diagnostic criteria are eligible. These diagnostic criteria can be met at any time during the course of the participant s malignancy. Atypical CML is not an eligible diagnosis.\n\nNOTE: Pathology reports are acceptable to confirm eligibility.\n\nMalignancy mutation and HLA requirements:\n\n* Detection of at least one of the neoepitope-forming TP53 or RAS mutations that are listed in Table 3 in on the TruSight Oncology (TSO) 500 sequencing panel (NSR device) performed in the NCI Laboratory of Pathology is required. RAS mutations can be in NRAS, KRAS or HRAS as these oncogenes have the same amino acid sequence at the location of the targeted neoepitopes. A variant allele frequency (VAF) of at least 5% is required for a mutation to be eligible. This criterion can be met at any time within 60 days prior to apheresis regardless of treatment history during this 60-day period. DNA for sequencing comes from bone marrow.\n* Presence of the correct HLA type needed to present one of the targeted neoepitopes as shown in Table 3. HLA typing data from any time-point prior to apheresis can be used to meet this requirement.\n\nTable 3: Eligibility requirements for the targeted mutation and HLA type\n\nTargeted mutation - TP53 R175H; HLA Type - A\\*02:01\n\nTargeted mutation - TP53 Y220C; HLA Type - A\\*02:01\n\nTargeted mutation - TP53 R248W; HLA Type - A\\*68:01\n\nTargeted mutation - Ras G12V; HLA Type - A\\*11:01\n\nTargeted mutation - Ras G12D; HLA Type - A\\*11:01\n\nTargeted mutation - Ras G12D; HLA Type - C\\*08:02\n\nTargeted mutation - Ras G12V; HLA Type - C\\*01:02\n\nMalignancy burden requirements:\n\n* For AML and MDS, bone marrow myeloblast percentage must be \\>=5% of nucleated cells in either bone marrow aspirate or biopsy. Myeloblasts can be defined by immunohistochemistry or by cytochemistry stains including but not limited to myeloperoxidase.\n* For T-ALL, bone marrow T-cell blast percentage must be \\>=5% of nucleated cells in either bone marrow aspirate or biopsy. T cells can be defined by cytochemistry or immunohistochemistry or flow cytometry.\n* For multiple myeloma, plasma cells having a phenotype consistent with multiple myeloma must be detected at any frequency by multiparameter bone marrow flow cytometry or total plasma cells must be at least 6% on bone marrow core biopsy or bone marrow aspirate.\n* For CMML, bone marrow blast (including monocytic blast equivalent) percentage must be \\>=6% of bone marrow nucleated cells by cytochemistry or immunohistochemistry of bone marrow aspirate or biopsy.\n* For CML measurable leukemia is defined as molecular detection of BCR-ABL1 at a ratio of \\>1.0% to ABL1 or another housekeeping gene on The International Scale (IS) in either blood or bone marrow.\n\nMalignancy prior treatment and risk category criteria\n\n\\- Participants with AML, MDS, CML, CMML, and T-ALL who have not had prior allogeneic hematopoietic stem cell transplantation (alloHSCT) must be unwilling or unable to undergo alloHSCT.\n\nNOTE: Unable to undergo alloHSCT could be due to lack of access to transplantation or not meeting transplant eligibility criteria at one or more transplant centers where the participant was evaluated by a transplant physician.\n\n* Participants with primary, secondary, or treatment-related AML that did not go into remission after induction therapy are eligible regardless of history of alloHSCT.\n* Myelodysplastic syndrome (MDS)\n\n  * Participants with MDS must have had high or very high risk MDS as determined by IPSS-R or IPSS-M (https:\u002F\u002Fmds-risk-model.com) at any time point.\n  * Participants with MDS must have received previous treatment with at least one of the following: a hypomethylating agent, cytotoxic chemotherapy, or alloHSCT. Participants with primary or treatment-related MDS are eligible.\n  * Participants with MDS\u002FAML with mutated TP53 are eligible.\n* Participants with CMML must have had a CMML-specific prognostic scoring system-Molecular (CPSS-Mol) score of \\>=2 (Intermediate-2 or High risk groups) at any time-point and must have received at least one line of previous systemic treatment, which could have been alloHSCT.\n* Chronic myeloid leukemia (CML)\n\n  * Participants with chronic phase CML and a history of inadequate response to or intolerance of 3 or more tyrosine kinase inhibitors (TKIs) are eligible.\n  * In addition, participants who have received at least one of bosutinib, dasatinib, or nilotinib in addition to either ponatinib or asciminib are eligible. Participants in accelerated phase or blast crisis are eligible if they have received at least one TKI.\n  * Participants who have received a prior HSCT are eligible provided they have also received at least 2 TKIs and meet other eligibility criteria.\n* Participants with T-ALL must have T-ALL that did not go into CR with induction therapy or that relapsed.\n* Participants with relapsed AML who are unable to undergo alloHSCT and meet other eligibility requirements are eligible.\n* Multiple Myeloma\n\n  * Participants with multiple myeloma must have received at least 3 different prior systemic treatment regimens for multiple myeloma. Participants must have prior exposure to an imid such as lenalidomide, a proteosome inhibitor, and a BCMA-targeting CAR T-cell therapy, such as monoclonal antibody, or bispecific antibody.\n  * Multiple myeloma participants with a history of alloHSCT are eligible\n  * Participants with multiple myeloma must also have measurable multiple myeloma\n\ndefined by at least one of the criteria below:\n\n* Serum M-protein greater or equal to 1.0 g\u002FdL.\n* Urine M-protein greater or equal to 200 mg\u002F24 h.\n* Serum free light chain (FLC) assay: involved FLC level greater or equal to 10mg\u002FdL (100 mg\u002FL) provided serum FLC ratio is abnormal.\n* A biopsy-proven plasmacytoma at least 2.0 cm in largest dimension.\n* Bone marrow core biopsy with 30% or more plasma cells.\n\nOther inclusion criteria\n\n* Blast cells \\\u003C=1% of white blood cells as measured by CBC and differential before apheresis\n* Plasma cells \\\u003C=1% of white blood cells as measured by CBC and differential before apheresis\n* Participants must be willing to undergo intensive care unit care including mechanical ventilation if necessary\n* Participants must not have received systemic chemotherapy for at least 14 days prior to start of lymphodepleting chemotherapy or apheresis, and chemotherapy-related toxicities other than cytopenias must have recovered to grade 0 or grade 1 by the time of apheresis. The one exception is if necessary to control AML, CML, or CMML, hydroxyurea can be administered up to 7 days prior to apheresis.\n* Participants who have received alloHSCT must have received a transplant from either a fully matched sibling or 10\u002F10 HLA-matched unrelated donor.\n* Recipients of alloHSCT must be at least 100 days post-transplant before the apheresis.\n* Subjects must be willing to be co-enrolled on NCI protocol 03C0277 and 09C0161.\n* Age must be \\>=18 and \\\u003C= 75 years old\n* Clinical performance status of ECOG 0 or 1\n* Participants must have adequate organ function as defined below:\n\n  * Hemoglobin: \\>=8 g\u002FdL without red blood cell transfusions for 7 days prior to blood count check\n  * Platelets: \\>=45,000\u002FmcL without transfusion support in the 7 days prior to the blood count check\n  * Absolute neutrophil count: \\>=850\u002FmcL without exogenous growth factor administration within the 10 days prior to the blood count check\n  * Total bilirubin: \\\u003C= 2.0 mg\u002FdL. Except for participants with Gilbert s syndrome (who must have a total bilirubin \\\u003C3 mg\u002FdL)\n  * Alanine transaminase (ALT) and aspartate transaminase (AST): \\\u003C= to 3 times the upper limit of the institutional normal unless liver involvement by malignancy is demonstrated. If liver involvement with malignancy is detected, ALT and AST must be \\\u003C= 5 times the upper limit of normal\n  * Serum Creatinine: \\\u003C= 1.5 mg\u002FdL\n* Participants who have received prior genetically-engineered T-cell therapies are eligible if at least 180 days have elapsed between the date of previous T-cell infusion and apheresis.\n* Room air oxygen saturation must be 93% or greater\n* Women of child-bearing potential (WOCBP) must agree to use highly effective contraception (hormonal, intrauterine device \\[IUD\\], abstinence, surgical sterilization) starting at the time of study entry, for the duration of study therapy, and 12 months after the last dose of combined chemotherapy. NOTE: IOCBP is defined as any person who has experienced menarche and who has not undergone successful surgical sterilization or who is not postmenopausal.\n\nMen able to father children must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and for 4 months after the last dose of combined chemotherapy. We also will recommend these Men with partners of childbearing potential ask their partners to be on highly effective birth control (hormonal, intrauterine device \\[IUD\\], surgical sterilization). Men able to father a child must not freeze or donate sperm within the same period.\n\n* Nursing participants must be willing to discontinue breastfeeding from study treatment initiation through 4 months after the last dose of the study drug(s).\n* Hepatitis B surface antigen and hepatitis B core antibody tests must be negative. If either of these tests are positive, participants must have a negative blood PCR test for hepatitis B to enroll on the study.\n* Hepatitis C antibody test must be negative. If this test is positive, participants must have a negative blood PCR test for hepatitis C RNA to enroll on the study.\n* Cardiac ejection fraction of greater than or equal to 50% by echocardiography with no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram within 30 days prior to apheresis.\n* All participants must be willing to undergo mandatory bone marrow biopsy\u002F aspirates during the study.\n* Participants with a history of cigarette smoking of \\>5 pack years, a history of pulmonary disease, a history of alloHSCT, or chronic pulmonary symptoms must undergo pulmonary function testing and have an FEV1 \\>50% predicted and diffusing capacity for carbon monoxide \\>= 60%.\n* Subjects who received a previous allogeneic HSCT must have no (grade 0) acute GVHD and no chronic GVHD or mild chronic GVHD as defined.\n\n  --NOTE: Subjects with GVHD meeting the above criteria with local therapy (topical cutaneous steroids, inhaled steroids, and eye drops) will be eligible.\n* Potential participants must agree to stay within 1-hour drive of NIH clinical center from date of initial discharge until at least 14 days have elapsed since T cell infusion through the 14 day time period.\n* Ability of the participant to understand and the willingness to sign a written informed consent document.\n* Willing to sign a durable power of attorney.\n\nEXCLUSION CRITERIA:\n\n-For alloHSCT recipients only, subjects receiving any systemic immunosuppressive drugs including corticosteroids at doses of greater than 5 mg\u002Fday prednisone or equivalent within 28 days prior to apheresis.\n\nNOTE: Topical corticosteroid preparations applied to the skin such as solutions, creams, and ointments are allowed. Inhaled corticosteroids are allowed, and corticosteroid eye drops are allowed.\n\n* Corticosteroids given for any indication at doses greater than 5 mg\u002Fday of prednisone or equivalent within 14 days before either apheresis or start of protocol chemotherapy.\n* Participants with MDS\u002FMyeloproliferative neoplasia overlap syndromes are not eligible.\n* Participants with acute promyelocytic leukemia are not eligible.\n* Participants who received a mis-matched sibling or haploidentical transplant are not eligible.\n* Tumor masses \\>=10 cm in largest diameter\n* Positive beta Human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test in IOCBP performed at screening.\n* Human T-cell lymphotropic virus type 1\u002F 2 (HTLV-1\u002FII) positive\n* HIV infection, as measured by seropositivity for HIV antibody.\n* Participants that require urgent therapy due to tumor mass effects on vital organ or tumor lysis syndrome.\n* Any significant illness that, in the opinion of the principal investigator, may impair the participant s tolerance of the study treatment as evaluated by medical history, physical exam, assess for hepatosplenomegaly, and chemistry laboratory evaluations.\n* Participants with a history of a previous malignancy are ineligible if the malignancy has not been in complete remission for at least 2 years or if the previous malignancy required treatment with surgery, radiation, or chemotherapy, including maintenance hormonal therapy, in the past 2 years. Exceptions to this requirement are participants who have had successful resection of the following types of skin cancer: nonmetastatic basal cell carcinoma or squamous cell carcinoma or stage 0 melanoma.\n* Suspected or confirmed active uncontrolled infections defined as fevers of \\>38 degrees within the past 24 hours without a known non-infectious source or participants requiring intravenous antibiotics when intravenous antibiotics have been administered for less than 72 hours.\n* Acti...","ALL","18 Years","120 Years",{"count":20,"type":21},86,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Background:\n\nBlood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes. Researchers want to test a method of treating blood cancers by altering a person s T cells (a type of immune cell) to target neoepitopes.\n\nObjective:\n\nTo test the use of neoepitope-specific T cells in people with blood cancers\n\nEligibility:\n\nPeople aged 18 to 75 years with any of 9 blood cancers.\n\nDesign:\n\nParticipants will have a bone marrow biopsy: A sample of soft tissue will be removed from inside a pelvic bone. This is needed to confirm their diagnosis and the TP53 and RAS mutations in their cancer cells. They will also have a skin biopsy to look for these mutations in other tissue.\n\nParticipants will undergo apheresis: Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein.\n\nThe T cells will be grown to become neoepitope-specific T cells.\n\nParticipants receive drugs for 3 days to prepare their body for the treatment. The modified T cells will be given through a tube inserted into a vein. Participants will need to remain in the clinic at least 7 days after treatment.\n\nParticipants will have 8 follow-up visits in the first year after treatment. They will have 6 more visits over the next 4 years. Long-term follow-up will go on for 10 more years.",[27,28,29,30,31,32,33,34,35,36,37],"Malignancy, Hematologic","Neoplasms, Hematologic","Neoplasms, Hematopoietic","Blood Cancer","Hematological Neoplasms","Hematopoietic Malignancies","Dysmyelopoietic Syndromes","Hematopoetic Myelodysplasia","Myeloid Leukemia, Acute","Nonlymphoblastic Leukemia, Acute","Leukemia, Lymphocytic, Acute",[39,40,41,42,43,44,45,46,47,48],"Chronic Myelomonocytic Leukemia","Multiple Myeloma","Tumor-Associated Antigen","T-cell acute lymphoblastic leukemia","T cell immunotherapy","Myelodysplastic Syndrome","Hematologic Malignancies","Engineered T cell receptor","Chronic Myeloid Leukemia","Adoptive T Cell Therapy","RECRUITING","2026-07-10",{"date":52,"type":53},"2026-07-13","ACTUAL",{"date":55,"type":21},"2026-07-16",{"date":57,"type":21},"2029-04-30",{"name":59,"class":60},"National Cancer Institute (NCI)","NIH",1,{"id":63,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":25,"conditions":66,"keywords":67,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":74,"locationsCount":61},"100585569",{"count":20,"type":21},[24],[27,28,29,30,31,32,33,34,35,36,37],[39,40,41,42,43,44,45,46,47,48],"2026-07-01",{"date":70,"type":53},"2026-07-02",{"date":72,"type":21},"2026-07-07",{"date":57,"type":21},{"name":59,"class":60},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":61},"100553163","phase-2-take-the-reins-the-effects-of-nutrient-timing-on-cancer-related-fatigue-100553163","NCT06482515","Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue","Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue Among Blood Cancer Survivors (2458GCCC)","Inclusion criteria (Participants must…):\n\n* Have a diagnosis of a hematologic neoplasm (e.g., leukemia, lymphoma, multiple myeloma);\n* Be at least 2 months post-treatment with chemotherapy, radiation, targeted therapy, chimeric antigen receptor (CAR)-T cell therapy, stem cell transplant, or another therapy (maintenance therapies are okay; steady unchanged treatment for relapsed disease for \\>2 months and expected to stay on it until progression is okay);\n* Have a baseline level of fatigue, as determined by at least one of the following:\n\n  1. Reporting a score of 4 or higher in response to the question, \"What was your worst fatigue in the last week, on a scale of 0-10, where 0 is no fatigue and 10 is the worst fatigue?\"\n  2. In the habit of taking daytime naps,\n  3. Have fatigue that interferes with their ability to work, engage in social events, or is more than would be expected from physical exertion,\n* Be able to speak and\u002For read and write in English or Spanish;\n* Be at least 18 years old; and\n* Be able to provide informed consent.\n\nExclusion criteria (participants must not…)\n\n* Be underweight, as defined as a body mass index \\\u003C18.5 kg\u002Fm2;\n* Already eat all their food within a window that is 10 h or shorter most (6\u002F7) days of the week;\n* Be employed in a job where they regularly work away from the home at night (e.g., night shift);\n* Have surgery planned during the study duration;\n* Have any contraindications to the proposed nutrition intervention as identified by their medical provider, their designee, or the study team (e.g., type 1 diabetes, risk for hypoglycemia, medication requirements, pregnancy, breastfeeding, recent history of an eating disorder);\n* Be taking insulin; or\n* Be on enteral or parenteral nutrition.",{"count":83,"type":21},96,[85],"PHASE2","Cancer-related fatigue affects at least 30-90% of patients with cancer, depending on the type of cancer and their treatment(s) (e.g., chemotherapy, radiation). It is not relieved by sleep or rest, and it sometimes can persist for years after a person's cancer was treated. The fatigue can be so bad that people cannot return to work, hobbies, family roles, or other daily activities, thereby greatly reducing quality of life. The causes of this fatigue are unknown, and we currently do not have anything that can reliably prevent or cure the fatigue. However, there are recent data suggesting that circadian rhythm, or a person's internal body clock, may be disrupted by the cancer experience and contribute to fatigue. Food intake is an external cue that can entrain circadian rhythm. We recently showed that cancer survivors are willing and able to eat all their food within a 10-hour eating window-a practice called time-restricted eating. Herein, we are testing time-restricted eating against a control group (matched for time-, attention, and expectancy) to see if time-restricted eating can indeed alleviate cancer-related fatigue. All participants will be asked to use the myCircadianClock smartphone app to log their food intake and weekly body weight measurements. The participants assigned to the time-restricted eating group will be asked to eat all their food in a 10-hour window during the day. People can choose their start time based on their schedule and preferences, but we ask that the window is the same for the whole study (e.g., 7am-5pm,9:30am-7:30pm). Black coffee and unsweetened tea are allowed before the eating window, and water and medicines are allowed at all times. The participants in the control group will meet with a nutritionist to discuss the American Cancer Society nutrition guidelines in cancer survivorship; they will not be restricted to when they can eat. Participants in both groups will give us valuable information regarding how diet is related to the experience of fatigue. The purpose of this study is to test the effects of a 12-week TRE intervention vs. an unrestricted eating pattern on fatigue, the sustainability of the program at 24 weeks, and the effects of TRE on circadian rhythm and sugar metabolism.",[88,30,89,90,91,92],"Neoplasms","Fatigue","Diet Habit","Survivorship","Fasting, Intermittent","2026-06-03",{"date":95,"type":53},"2026-06-05",{"date":97,"type":53},"2024-11-04",{"date":99,"type":21},"2028-08-31",{"name":101,"class":102},"University of Maryland, Baltimore","OTHER",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":61},"100552147","driving-inclusivity-validity-and-equity-in-research-through-strategic-engagement-diverse-100552147","NCT06469307","Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)","DIVERSE","CAB Participant Inclusion Criteria:\n\n* Age 18 or older\n* English speaking\n* Ability to understand and willingness to provide oral consent\n* DFCI patient who are in remission from a blood cancer \\>1 year will be preferred.\n\nCAB Participant Exclusion Criteria:\n\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers \\\u003C18 years old)\n* Prisoners.\n* Unwilling\u002Funable to agree to maintaining the confidentiality of reviews and clinical trial materials, as outlined in Section 9.1\n* Note 1: Patients and non-patient community members who are pregnant are eligible. This is a non-interventional study that meets the definition of minimal risk and poses no greater risk to pregnant individuals or fetuses. Pregnancy status will not be assessed.\n* Note 2: English fluency is necessary as protocols being reviewed are written in English and cannot be feasibly translated to other languages within the time period necessary to complete timely reviews.\n\nInvestigator Participant Inclusion Criteria:\n\n* Age 18 older\n* English Speaking\n* Site or Principal investigator\n* Not a member of the research team",true,{"count":112,"type":21},40,[114],"NA","The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.",[30,117],"Leukemia",[30,117],"2026-05-26",{"date":121,"type":53},"2026-05-28",{"date":123,"type":53},"2024-12-09",{"date":125,"type":21},"2027-06-30",{"name":127,"class":102},"Dana-Farber Cancer Institute",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":110,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100597010","a-music-therapy-study-for-blood-cancer-survivors-with-cognitive-difficulties-100597010","NCT07052916","A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties","Pilot Trial of Telehealth Music Therapy for Cognitive Dysfunction in Hematologic Cancer Survivors (PRELUDE)","Inclusion Criteria:\n\n* English-proficient, aged 18 or older\n* Diagnosis of lymphoma, leukemia, or myeloma\n* Stable oncologic disease or no evidence of disease as indicated in the medical chart or by the oncology team\n* Score of \\\u003C54 on the FACT-Cog PCI subscale\n* Minimum life expectancy of one year as per clinician assessment\n* Patient should be able to understand and complete all study assessments on their own.\n* Eligible patient should be able to understand informed consent and provide signed informed consent in English.\n\nExclusion Criteria:\n\n* Less than 3 months since completion of surgery, radiation, induction chemotherapy (for newly diagnosed or relapsed disease), transplantation, or immunotherapy (e.g., CAR T-Cell, bispecific antibodies)\n\n  * If there is a defined treatment period, the patient must be at least 3 months from treatment completion\n  * If the patient is on continuous therapy, patient must have completed at least 6 months of the therapy\n  * Maintenance therapies are allowed\n* Received music therapy (MT) in the past year\n* Current music training, \\>6 months of music training in the past 10 years, or plan to initiate music training during the study\n* No access to an internet-connected device\n* Active suicidal ideation, bipolar, schizophrenia, or substance abuse\n* BOMC score ≥10 (indicative of dementia)\n* Uncorrectable visual, auditory, or motor impairments\n* Initiation or altered dose of sedative, stimulant, or anti-cholinergic medications in the past month or plan to initiate these medications during the study, as these are known to impact cognitive function\n* Initiation of any other interventions for CRCD (e.g., cognitive rehabilitation) in the past month or plan to initiate these interventions during the study, as these are known to impact cognitive function",{"count":136,"type":21},60,[114],"Research has shown that music-based activities may help improve brain functions, such as attention, memory, and executive function. Because of this past research, the researchers are doing this study to find out whether telehealth music therapy is a practical treatment for cognitive difficulties in blood cancer survivors. The researchers will also study whether music therapy and music education help improve cognitive function and other common symptoms such as anxiety, depression, and\u002For tiredness.",[30,140,117,141],"Lymphoma","Myeloma",[143,144,117,140,145,146],"Blood cancer survivor","myeloma","Memorial Sloan Kettering Cancer Center","25-119","2026-05-22",{"date":119,"type":53},{"date":150,"type":53},"2025-06-27",{"date":152,"type":21},"2026-12-27",{"name":145,"class":102},7,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":61},"100488935","defining-the-role-of-palliative-care-for-patients-with-hematologic-malignancies-undergoing-adoptive-cellular-therapy-100488935","NCT05646576","Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy","Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy: The PEACE Study","PEACE","Inclusion Criteria:\n\n* Age 18 years or older.\n* Ability to complete surveys in English or with assistance of an interpreter.\n* Diagnosis of a hematologic malignancy.\n* Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product.\n\nExclusion Criteria:\n\n* Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment.\n* Already receiving palliative care (PC).",{"count":164,"type":21},90,[114],"The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups.\n\nThe names of the study intervention groups involved in this study are:\n\n* Palliative care (PEACE) plus usual oncology care\n* Usual care (standard oncology care)\n\nParticipation in this research study is expected to last for up to 2 years.\n\nIt is expected that about 90 people will take part in this research study.",[168,30,140,117,40],"Hematologic Malignancy",[168,170,171,140,117,40,172],"Adoptive Cellular Therapy","Palliative Care Intervention","Palliative Care","2026-04-16",{"date":175,"type":53},"2026-04-21",{"date":177,"type":53},"2022-12-30",{"date":179,"type":21},"2027-04-01",{"name":181,"class":102},"Massachusetts General Hospital",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":110,"sex":16,"minAge":190,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":199,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":154},"100555331","phase-2-pharmacogenomics-for-better-treatment-of-fungal-infections-clinical-trial-100555331","NCT06510699","Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial","Randomized Clinical Trial to Evaluate the Use of Genotype-based Dosing of Voriconazole","PRAGMATIC","Inclusion Criteria:\n\n* Age ≥ 2 years.\n* Written informed consent obtained.\n* Decision to prescribe voriconazole.\n* Admitted to a trial site, or sufficient outpatient follow-up appointments are feasible\n\nExclusion Criteria:\n\n* Post-allogeneic haematopoietic stem cell transplant (HCT) patient, without access to pre HCT DNA\n* Death is likely imminent within 7 days.\n* Previously randomised to this trial","2 Years",{"count":192,"type":21},104,[85],"This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally effective dosing regimens. This study investigates if voriconazole increases the proportion of patients achieving therapeutic exposure at day 8 of dosing compared with standard care; and will assess factors that influence the implementation of genotype testing and dosing software in the healthcare system, including fidelity, feasibility, acceptability and cost-effectiveness. It will recruit at least 104 kids and adults in a parallel-group randomised clinical trial. A hybrid feasibility sub-study will assess the scalability of genotype-directed dosing to ensure sustainable integration of the interventions into the clinical workflow. A health economic sub-study will evaluate the costs, health outcomes and cost-effectiveness of genotype-directed testing compared to standard care.",[196,197,30,198],"Fungal Infection","Haematological Malignancy","Infectious Disease",[200,201,202,203,204],"infection","cancer","pharmacogenomic","genotype-based dosing","CYP2C19","2026-04-13",{"date":173,"type":53},{"date":208,"type":53},"2025-04-14",{"date":210,"type":21},"2027-03-26",{"name":212,"class":102},"The University of Queensland",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":226,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":240},"100604335","phase-1-a-multi-site-break-through-cancer-trial-targeting-measurable-residual-disease-in-patients-with-acute-myeloid-leukemia-a-phase-12-study-of-tagraxofusp-azacitidine-and-venetoclax-100604335","NCT07148180","A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1\u002F2 Study of Tagraxofusp, Azacitidine, and Venetoclax","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* History of known diagnosis of Acute Myeloid Leukemia (including de novo, secondary or AML arising from MDS).\n* Subjects must be in CR, CRi, or CRh with \\\u003C5% morphologic blasts in bone marrow\n* Any evidence of CD123+ by central assessment.\n* Participants must have measurable disease, defined as ≥ 0.1% by multiparametric flow cytometric assay as assessed by central laboratory\n* ECOG performance status ≤2 (see Appendix A).\n* Subjects must have adequate organ and marrow function as defined below:\n\n  * total bilirubin ≤ 1.5 x institutional upper limit of normal unless due to Gilbert or non-hepatic in origin\n  * AST(SGOT) and ALT(SGPT) ≤ 3.0 × institutional upper limit of normal\n  * Creatinine clearance ≥ 45 ml\u002Fmin GFR by MDRD\n* Albumin ≥ 3.2 g\u002FdL\n* Left ventricular ejection fraction ≥ institutional lower limit of normal by MUGA or echocardiogram within 30 days of first protocol treatment. This can be locally assessed.\n* Pregnancy potential: Female subjects of childbearing potential must have negative results for pregnancy test. Females with reproductive potential are advised to use effective contraception during study treatment and for at least 6 months after last dose. Similarly, males with female partners of reproductive potential are advised to use effective contraception during treatment and for at least 3 months after the last dose. Men must agree to abstain from donating sperm.\n* Subject is able and willing to adhere to the study visit schedule and other protocol requirements\n\nExclusion Criteria:\n\n* Prior treatment with CD123-targeted therapy\n* Known diagnosis of acute promyelocytic leukemia.\n* Subjects who received intensive anti-leukemic chemotherapy within 2 weeks from first dose of study. If on venetoclax, subjects must be off venetoclax for at least 5 days\n* Subjects pre-arranged for SCT are only excluded if it is imminent.\n* History of prior allogeneic stem cell transplant\n* Subject has uncontrolled, clinically significant pulmonary disease (e.g. COPD, pulmonary hypertension, etc.) that in the opinion of the Investigator would put the subject at significant risk for pulmonary complications during the study.\n* Subject has experienced Grade 3 or Grade 4 capillary leak syndrome (CLS) in the past for any reason\n* Subjects with known HBV and\u002For HCV infection must have undetectable viral load during screening (HBV and HCV testing are not required.) Participants with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.\n* Subjects with known HIV positivity are permitted provided they have undetectable viral load at the time of screening (HIV testing is not required).\n* Subject has a concurrent malignancy or prior malignancy within the 6-month period before screening. To be eligible, subjects must be in remission from the prior malignancy at least 6 months prior to screening and all treatment-related toxicities must have resolved to ≤ Grade 1 except for alopecia. Exceptions include adequately treated basal or squamous cell skin cancer, superficial bladder cancer, adequately treated carcinoma in situ of the cervix or uterus, or carcinoma in situ of the breast, previous malignancy confined and surgically resected (or successfully treated with other modalities) with curative intent, which are permissible for inclusion. Maintenance therapy, hormonal therapy, or steroid therapy for a well-controlled concurrent malignancy is allowed.\n* Subject has uncontrolled systemic fungal, bacterial, or viral infection, defined as ongoing signs\u002Fsymptoms related to the infection without improvement despite appropriate antibiotics, antivirals, or antifungals, either IV or oral. However, subjects with controlled infection still requiring anti-infectives are eligible.\n* Subjects with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, that have New York Heart Association Functional Class III or IV symptoms.\n* Subject has evidence of ongoing alcohol or drug abuse\n* Subjects with known active\u002Fsymptomatic CNS involvement. CNS prophylaxis allowed\n* Subjects receiving moderate or strong P450 3A (CYP3A) inducers within 7 days of start of study therapy. See Appendix B for examples\n* Subjects with uncontrolled intercurrent illness.\n* Administration or consumption of any of the following within 3 days prior to the first dose of study drug:\n\n  * grapefruit or grapefruit products\n  * Seville oranges (including marmalade containing Seville oranges)\n  * star fruit\n* Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with trial therapy, breastfeeding should be discontinued if the mother is treated on trial.",{"count":220,"type":21},31,[24,85],"The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This research study is to determine if the combination therapy can safely help to control residual Acute Myeloid Leukemia (AML) and to prevent disease recurrence.\n\nThe names of the study drugs involved in this study are:\n\n* Tagraxofusp (a type of CD123-directed cytotoxin)\n* Azacitidine (a type of standard of care cytidine nucleoside analog)\n* Venetoclax (a type of standard of care BCL-2 inhibitor)",[224,117,30,225],"Acute Myeloid Leukaemia (AML)","Blood Cancers",[227,228,229,230,30,225],"Acute Myeloid Leukemia","AML","Measurable Residual Disease","Myeloid Neoplasms","2026-02-03",{"date":233,"type":53},"2026-02-05",{"date":235,"type":53},"2026-02-02",{"date":237,"type":21},"2030-12-31",{"name":239,"class":102},"Jacqueline Garcia, MD",2,{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":248,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":250,"phases":4,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":61},"100616398","development-of-a-multi-biomarker-panel-for-prognostic-stratification-and-treatment-response-prediction-in-acute-graft-versus-host-disease-of-the-gut-100616398","NCT07305090","Development of a Multi-biomarker Panel for Prognostic Stratification and Treatment Response Prediction in Acute Graft Versus Host Disease of the Gut","GUT-PREDICTION","Inclusion Criteria:\n\n* Patients aged ≥ 12 years\n* Indication for allogeneic HSCT\n* Obtaining informed consent\n\nExclusion Criteria:\n\n* None","12 Years",{"count":164,"type":21},"OBSERVATIONAL","Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a life-saving treatment for many malignant hematologic diseases. Its curative potential is due to both high-dose chemotherapy and the graft-versus-host disease (GvHD) process, in which the donor's T cells recognize the recipient's tissue as foreign. However, GvHD is a potentially fatal complication that significantly affects both survival and quality of life. GvHD can be acute or chronic, and one of the main target organs involved in acute GvHD is the intestine, with a high rate of treatment failure and mortality. We expect to identify a set of biomarkers, both clinical and experimental, that will enable the stratification of patients based on prognosis and response to treatment in intestinal GvHD. The ultimate goal of the study is to integrate clinical, transplant, and biomarker data into a robust predictive algorithm. This tool will enable personalized therapeutic approaches based on early biomarkers, improving prognostic accuracy for patient outcomes and optimizing therapeutic strategies.",[30],[254,255,256],"GvHD","aGvHD","GI","2026-01-08",{"date":259,"type":53},"2026-01-09",{"date":261,"type":53},"2025-10-15",{"date":263,"type":21},"2028-02-01",{"name":265,"class":102},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":250,"phases":4,"briefSummary":274,"conditions":275,"keywords":278,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":61},"100524999","immune-profiling-for-cancer-immunotherapy-response-100524999","NCT06116032","Immune Profiling for Cancer Immunotherapy Response","Inclusion Criteria:\n\n* Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).\n* Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).\n\nExclusion Criteria:\n\n* Pregnant women\u002Ffetuses\u002Fneonates\n* Prisoners\n* Decision-impaired individuals",{"count":273,"type":21},1500,"In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.",[276,277,168,30],"Cancer","Tumor, Solid",[279],"Immunotherapy","2025-12-09",{"date":282,"type":53},"2025-12-16",{"date":284,"type":53},"2022-10-03",{"date":286,"type":21},"2029-01-01",{"name":288,"class":102},"Dartmouth-Hitchcock Medical Center",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":297,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":307,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":61},"100551092","effect-of-apa-on-sleep-quality-in-children-with-cancer-from-5-to-16-years-100551092","NCT06455592","Effect of APA on Sleep Quality in Children With Cancer From 5 to 16 Years","Effect of Practicing Adapted Physical Activity (APA) on Sleep Quality in Children From 5 Years of Age and Adolescents up to 16 Years of Age Undergoing Treatment for a Hematologic Malignancy.","APANYX","Inclusion Criteria:\n\n* Children from 5 to 16 with haematological cancer undergoing treatment\n* Subjects and their parents who were informed about the study and gave informed consent.\n* Enrollment in the Social Security system\n\nExclusion Criteria:\n\n* Children on high-dose corticosteroids\n* Children under anxiolytic treatment\n* Children with sleep disorders (sleep apnea)\n* Children taking melatonin or sleeping pills\n* Contraindication to adapted physical activity\n* Refusal to participate on the part of the participant or his\u002Fher parents\n* Holders of parental authority under curatorship, guardianship, safeguard of justice\n* Pregnant or breast-feeding teenagers","5 Years","16 Years",{"count":300,"type":21},30,[114],"Main objective :\n\nEvaluate the effect of adapted physical activity on the sleep of children with cancer from 5 to 16\n\nHypothesis :\n\nPractice daily adapted physical activity improve the sleep of the 5 to 16 children with cancer",[304,30,305,306],"Child, Only","Adapted Physical Activity","Sleep",[308,309,310,311,312],"child","blood cancer","adapted physical activity","sleep","hospital and home","2025-12-01",{"date":315,"type":53},"2025-12-05",{"date":317,"type":53},"2025-11-17",{"date":319,"type":21},"2027-11",{"name":321,"class":102},"University Hospital, Clermont-Ferrand",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":339,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":351},"100525280","phase-1-idp-023-as-a-single-agent-and-in-combination-with-antibody-therapies-in-patients-with-advanced-hematologic-cancers-100525280","NCT06119685","IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","Phase 1\u002F2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","Key Inclusion Criteria:\n\n* For MM patients: Documented diagnosis of MM requiring systemic therapy and relapsed and\u002For refractory (R\u002FR) disease after ≥ 3 prior lines of therapy.\n* For NHL patients: R\u002FR disease and failed ≥ 2 lines of systemic chemotherapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy of greater than 12 weeks per the Investigator.\n\nKey Exclusion Criteria:\n\n* Impaired cardiac function or history of clinical significant cardiac disease.\n* Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.\n* Active SARS-CoV-2 infection.\n* Has untreated central nervous system, epidural tumor metastasis, or brain metastasis.",{"count":330,"type":21},128,[24,85],"This is an open label, Phase 1\u002F2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.",[334,40,30,335,336,337,338],"NHL","Refractory Non-Hodgkin Lymphoma","Relapsed Non-Hodgkin Lymphoma","Refractory Multiple Myeloma","Relapsed Multiple Myeloma",[340],"Advanced Hematologic Cancers","2025-05-30",{"date":343,"type":53},"2025-06-03",{"date":345,"type":53},"2023-10-25",{"date":347,"type":21},"2029-12-31",{"name":349,"class":350},"Indapta Therapeutics, INC.","INDUSTRY",12,{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":22,"phases":360,"briefSummary":361,"conditions":362,"keywords":364,"overallStatus":377,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":61},"100578935","development-of-an-intervention-integrating-procedures-combining-hypnosis-and-virtual-reality-in-the-support-of-patients-with-hematological-cancer-100578935","NCT06817759","Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer","Study Protocol for the Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Myeloma and Lymphoma During Stem Cell Transplant: a Pilot Randomized Clinical Trial","Inclusion Criteria:\n\n* Being 18 years of age or older\n* Suffering from multiple myeloma or lymphoma eligible for transplant\n* Understanding French\n\nExclusion Criteria:\n\n* Deafness\n* Blindness\n* Confusion or psychopathological disorders (for example, schizophrenia) that may impair communication",{"count":136,"type":21},[114],"Research into cancer patients has shown that quality of life is significantly altered by the disease and its associated treatments and is also reported to be a predictor of significant emotional distress. Blood cancer patients are among those most affected in terms of quality of life, facing stem cell transplantation after high-dose chemotherapy, a treatment that is recognized as one of the most stressful of cancer therapy, due to the many adverse effects, including pain, and the uncertainty linked to the fear of graft failure. Hypnosis interventions are proving effective in treating common side effects: nausea, pain, fatigue, anxiety, depressive symptoms and improving overall quality of life, and other interventions, based on virtual reality, have shown promising effects on patients' distress and acute pain. The aim of this study is to evaluate the effects of an intervention program combining hypnosis and virtual reality in assisting myeloma and lymphoma patients during stem cell transplantation, with a view to improving their quality of life during this period. The project aims to assess the validity of the intervention, and to evaluate the effects of the intervention on patients' anxiety, pain and fatigue during transplantation. The validity of the intervention will be measured by a questionnaire assessing the relevance and acceptability of the intervention, expected effects, and practical implementation. Socio-demographic and clinical data will be collected from patients, including axiety, pain, fatigue and quality of life, studied at pre (one week after transplantation) and post (one month after transplantation) intervnention, and at follow-up (three month after transplantation).",[30,363,140],"Multiple Myeloma (MM)",[365,366,367,368,369,370,371,372,373,374,375,376],"Virtual reality hypnosis","Quality of life","Blood cancer","Oncology","multiple myeloma","lymphoma","hypnosis","virtual reality","hematology","anxiety","pain","stem cells transplantation","NOT_YET_RECRUITING","2025-02-04",{"date":380,"type":53},"2025-02-10",{"date":382,"type":21},"2025-02",{"date":384,"type":21},"2025-12",{"name":386,"class":102},"Ciusss de L'Est de l'Île de Montréal",{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":110,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":250,"phases":4,"briefSummary":397,"conditions":398,"keywords":400,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":61},"100398278","better-leukemia-diagnostics-through-ai-beluga-100398278","NCT04466059","Better Leukemia Diagnostics Through AI (BELUGA)","A Case-Control Study To Determine The Suitability Of Artificial Intelligence For Leukemia Diagnostics","BELUGA","Inclusion Criteria:\n\n* Patients having been diagnosed with a suspected hematological disorder\n* The suspected diagnoses constitute a primary diagnosis\n* Only samples of patients min.18 years of age will be used\n* Samples must suffice quality attributes which are denoted in \"Exclusion Criteria\"\n\nExclusion Criteria:\n\n* The sample is not fit for state-of-the-art diagnosis or fails initial quality control. For quality insurance, we will exclude samples in heparin- instead of EDTA. Samples with damage due to atmospheric reasons (freeze-thaw damage or elevated temperature) will be excluded.\n* Samples with too scarce material jeopardizing routine gold-standard diagnosis will be excluded.\n* Bone marrow aspirates without sufficient material to assess malignant or healthy hematopoiesis.",{"count":396,"type":21},25000,"To the best of our knowledge, BELUGA will be the first prospective trial investigating the usefulness of deep learning-based hematologic diagnostic algorithms. Taking advantage of an unprecedented collection of diagnostic samples consisting of flow cytometry datapoints and digitalized blood-smears, categorization of yet undiagnosed patient samples will prospectively be compared to current state-of-the-art diagnosis at the Munich Leukemia Laboratory (hereafter MLL). In total, a collection of 25,000 digitalized blood smears and 25,000 flow cytometry datapoints will be prospectively used to train an AI-based deep neuronal network for correct categorization. Subsequently, the superiority will be challenged for the primary endpoints: sensitivity and specificity of diagnosis, most probable diagnosis, and time to diagnose. The secondary endpoints will compare the consequences regarding further diagnostic work-up and, thus, clinical decision making between routine diagnosis and AI guided diagnostics. BELUGA will set the stage for the introduction of AI-based hematologic diagnostics in a real-world setting.",[168,117,399,140,30],"Minimal Residual Disease",[373,401,402,403,404],"laboratory medicine","AI-based diagnostics","artificial intelligence","deep neuronal networks","2024-12-14",{"date":407,"type":53},"2024-12-17",{"date":409,"type":53},"2020-01-05",{"date":411,"type":21},"2025-07-31",{"name":413,"class":350},"Munich Leukemia Laboratory",{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":250,"phases":4,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":377,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":61},"100560220","clinical-evaluation-of-the-scopio-cell-morphology-technology-100560220","NCT06574308","Clinical Evaluation of the Scopio Cell Morphology Technology","Clinical Evaluation of the Scopio Cell Morphology Technology on Pre-classification of Blood Cells in Peripheral Blood (PB) and Bone Marrow (BM)","Hemascopio","Inclusion Criteria:\n\n* Patients suffering from hemopathies with bone marrow aspirate assessable under the optical microscope\n\nExclusion Criteria:\n\n* Patients not affected by blood disorders\n* Patients suffering from hemopathies with bone marrow aspirate that cannot be assessed under the optical microscope","80 Years",{"count":424,"type":21},300,"Digital morphology is currently expanding and developing new applications based on artificial intelligence software. We recently published a study comparing screen validation and microscopic reading of bone marrow aspirates. The aim of the current research will be the comparison between optical microscope reading and automatic pre-classification (AI based)",[30],"2024-08-26",{"date":429,"type":53},"2024-08-27",{"date":431,"type":21},"2024-09-01",{"date":433,"type":21},"2025-09-01",{"name":435,"class":102},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":22,"phases":446,"briefSummary":447,"conditions":448,"keywords":451,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":463,"locationsCount":61},"100453908","early-integration-of-palliative-and-supportive-care-in-cellular-therapy-100453908","NCT05190653","Early Integration of Palliative and Supportive Care in Cellular Therapy","Early Integration of Palliative and Supportive Care for Patients and Family Caregivers Undergoing Hematopoietic Stem Cell Transplantation or Chimeric Antigen Receptor T-Cell Therapy: A Prospective Pragmatic Randomized Clinical Trial","PALS_CT","Inclusion Criteria - Patients\n\n* Clinical diagnosis of hematologic malignancy with scheduled hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy\n* Ability to speak, read, and understand English or, be able to complete questionnaires with minimal assistance required from an interpreter\n\nInclusion Criteria - Family Caregivers\n\n* Family caregivers of patients with a clinical diagnosis of hematologic malignancy with scheduled hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy\n* A spouse, relative, or friend, identified by the patient, who either lives with the patient or has in-person contact with the patient at least twice per week. Only one family CG per patient will be asked to participate.\n* Ability to speak, read, and understand English or willing to complete questionnaires with minimal assistance required from an interpreter\n\nExclusion Criteria - Patients\n\n* Patients undergoing HSCT for a non-malignant hematologic condition\n* Inability to provide informed consent\n\nExclusion Criterion - Family Caregivers\n\n\\* Inability to provide informed consent",{"count":445,"type":21},152,[114],"Research has shown that early palliative care in cancer care is associated with improved symptom management, better prognostic understanding, improved quality of life for patients and family caregivers, and even improved survival. Yet, in spite of the proven benefits of integration of palliative care in oncology, it has been well established that patients with hematologic malignancies and those undergoing cellular therapy (hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor (CAR) T-cell therapy) do not routinely receive palliative care. Most of the published research on the early integration of palliative care in oncology describes studies that have involved patients with solid tumours. To date, only one randomized trial examining the impact of integrated palliative care among patients undergoing HSCT has been published and there have been no studies examining the impact of integrated palliative care for patients undergoing CAR T-cell therapy. The American Society of Clinical Oncology recommends early palliative care for patients with advanced cancers or for those with high symptom burden. Patients with blood cancers experience high symptom burden and in the last 30 days of life, compared to patients with solid tumours, patients with blood cancers are more likely to die in hospital, have more intensive care unit admissions, have prolonged hospitalizations (\\>14 days), and pass away in an acute care facility. There is an urgent need to proactively address suffering throughout cellular therapy trajectories, even before treatment starts, so that patients and caregivers are not inevitably waiting for symptoms to arise before they can be addressed and to optimize quality of life for patients undergoing transplant as well as their family caregivers.\n\nPALS\\_CT will compare early palliative care to standard care for patients and their family caregivers undergoing HSCT or CAR T-cell therapy for blood cancers.",[117,140,40,30,449,450],"Stem Cell Transplant Complications","Chimeric Antigen Receptor T-cell Therapy",[452,453,454,455,456],"palliative care","supportive care","quality of life","symptom burden","hematologic malignancies","2024-07-30",{"date":459,"type":53},"2024-07-31",{"date":461,"type":53},"2022-04-08",{"date":384,"type":21},{"name":464,"class":102},"Alberta Health Services, Calgary",{"id":466,"slug":467,"hasResults":11,"nctId":468,"briefTitle":469,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":472,"enrollmentInfo":473,"targetDuration":475,"studyType":250,"phases":4,"briefSummary":476,"conditions":477,"keywords":487,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":61},"100535343","european-rare-blood-disorders-platform-enrol-100535343","NCT06250595","European Rare Blood Disorders Platform (ENROL)","ENROL","Inclusion Criteria:\n\n* Patients must meet all of the following criteria to be included in the ENROL Registry\n* Age from 0-100, both female and male\n* Diagnosed as RHDs according to ORPHANET classification\n* Able and willing to provide written informed consent (patient or legal representative for minors) if needed according to national legislation.\n\nExclusion Criteria:\n\n* Patients diagnosed as traits or trait conditions for other recessive RHDs","100 Years",{"count":474,"type":21},37090,"15 Years","ENROL, the European Rare Blood Disorders Platform has been conceived in the core of ERN-EuroBloodNet as an umbrella for both new and already existing registries on Rare Hematological Diseases (RHDs). ENROL aims at avoiding fragmentation of data by promoting the standards for patient registries' interoperability released by the EU RD platform.\n\nENROL's principle is to maximize public benefit from data on RHDs opened up through the platform with the only restriction needed to guarantee patient rights and confidentiality, in agreement with EU regulations for cross-border sharing of personal data.\n\nAccordingly, ENROL will map the EU-level demographics, survival rates, diagnosis methods, genetic information, main clinical manifestations, and treatments in order to obtain epidemiological figures and identify trial cohorts for basic and clinical research. To this aim, ENROL will connect and facilitate the upgrading of existing RHD registries, while promoting the building of new ones when \u002F where lacking. Target-driven actions will be carried out in collaboration with EURORDIS for educating patients and families about the benefits of enrolment in such registries, including different cultural and linguistic strategies.\n\nThe standardized collection and monitoring of disease-specific healthcare outcomes through the ENROL user-friendly platform will determine how specialized care is delivered, where are the gaps in diagnosis, care, or treatment and where best to allocate financial, technical, or human resources.\n\nMoreover, it will allow for promoting research, especially for those issues that remain unanswered or sub-optimally addressed by the scientific community; furthermore, it will allow promoting clinical trials for new drugs. ENROL will enable the generation of evidence for better healthcare for RHD patients in the EU as the ultimate goal.\n\nENROL officially started on 1st June 2020 with a duration of 36 months. ENROL is co-funded by the Health Programme of the European Union under the call for proposals HP-PJ-2019 on Rare disease registries for the European Reference Networks. GA number 947670",[478,479,480,481,141,482,483,117,484,485,30,486],"Anemia","Bone Marrow Failure","Bleeding Disorder","Iron Metabolism Disorders","Lymphoid Neoplasm","Myeloma, Malignant","Anemia, Sickle Cell","Thalassemia","Red Cell Membrane and Enzyme Abnormalities",[478,479,488,489,490,491,367,117,492,485,493],"Bleeding disorder","Iron metabolism disorder","Myeloid","Lymphoid","Red Cell membrane and Enzyme Abnormalities","Sickle Cell Disease","2024-02-06",{"date":496,"type":53},"2024-02-09",{"date":498,"type":53},"2022-07-01",{"date":500,"type":21},"2037-07",{"name":502,"class":102},"Hospital Universitari Vall d'Hebron Research Institute",{"id":504,"slug":505,"hasResults":11,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":11,"sex":16,"minAge":298,"maxAge":510,"enrollmentInfo":511,"targetDuration":4,"studyType":22,"phases":512,"briefSummary":513,"conditions":514,"keywords":515,"overallStatus":377,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":4},"100469337","phase-1-allogeneic-t-cells-expressing-t-cell-receptor-kdel-and-the-chimeric-antigen-receptor-cat19-for-the-treatment-of-advanced-cd19-malignancies-100469337","NCT05391490","Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies","KCAT19","Inclusion Criteria:\n\n1. Age 16-65 years\n2. Relapsed or refractory B cell malignancy following at least 2 prior lines of therapy:\n\n   B-ALL: relapsed or refractory B-ALL following standard therapy, requiring salvage, in whom alternative therapies are deemed inappropriate by their treating physician Or LBCL: relapsed\u002Frefractory DLBCL (incl. transformed FL but not Richter's transformation) or PMBCL following ≥2 prior lines of therapy which must include Rituximab, anthracycline and autologous CD19 CAR, (unless CD19 CAR cannot be manufactured) Or MCL: relapsed\u002F refractory disease following ≥2 lines of therapy which must include Rituximab, Bruton's tyrosine kinase inhibitor and autologous CD19CAR therapy (unless CD19 CAR cannot be manufactured) Or Indolent B-NHL (either Follicular Lymphoma, Marginal Zone Lymphoma or other low-grade lymphoma) which is relapsed \u002F refractory following ≥2 prior lines of therapy which must include anti-CD20 therapy and chemotherapy with anthracycline or bendamustine.\n3. CD19+ disease\n4. Agreement to have a pregnancy test, use adequate contraception (if applicable)\n5. Written informed consent\n\nExclusion Criteria:\n\n1. CD19 negative disease\n2. Active CNS involvement of disease\n3. Diagnosis of chronic lymphocytic leukaemia\u002F small lymphocytic lymphoma or Burkitt lymphoma\n4. Active hepatitis B, C or HIV infection\n5. Oxygen saturation ≤ 90% on air\n6. Bilirubin \\>2 x upper limit of normal\n7. GFR \\\u003C30ml\u002Fmin\n8. Women who are pregnant or breast feeding\n9. Stem Cell Transplant patients only: active significant acute GvHD (overall Grade ≥ II, Modified Glucksberg criteria) or moderate\u002Fsevere chronic GvHD (NIH consensus criteria) requiring immunosuppressive therapy and\u002For systemic steroids\n10. Karnofsky score \\\u003C60%\n11. Known allergy to albumin or DMSO\n12. Patients receiving corticosteroids at a dose of \\>5 mg prednisolone per day (or equivalent) that cannot be discontinued\n13. Life expectancy \\\u003C3 months\n14. Cardiac dysrhythmias (excluding well-controlled AF or other supraventricular tachycardia) or significant cardiac disease and left ventricular ejection fraction \\\u003C40%\n15. Patients who can reasonably access autologous CD19 CAR treatment as part of standard of care or a clinical trial\\*\n\n    * These patients will be initially considered for autologous treatment in preference to enrolling on KCAT19","65 Years",{"count":351,"type":21},[24],"KCAT19 is a single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age 16-65 years) with high risk, relapsed\u002Frefractory (r\u002Fr) B cell malignancies.",[30],[516,517,370],"CAR T cells","leukemia","2022-05-20",{"date":520,"type":53},"2022-05-26",{"date":522,"type":21},"2022-10",{"date":524,"type":21},"2034-11",{"name":526,"class":102},"University College, London",{"id":528,"slug":529,"hasResults":11,"nctId":530,"briefTitle":531,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":11,"sex":16,"minAge":533,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":250,"phases":4,"briefSummary":536,"conditions":537,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":61},"100424392","the-leukemia-and-lymphoma-society-lls-national-research-registry-100424392","NCT04806295","The Leukemia and Lymphoma Society (LLS) National Research Registry","Inclusion Criteria:\n\nPeople with blood cancer, before, during, and after blood cancer treatments.\n\nExclusion Criteria:\n\nPeople unable or unwilling to sign informed consent.","21 Years",{"count":535,"type":21},1000,"The Leukemia and Lymphoma Society (LLS) has built a National Research Registry to evaluate real world experiences and medical outcomes for people with blood cancer, before, during, and after blood cancer treatments.",[30],"2022-04-05",{"date":540,"type":53},"2022-04-07",{"date":542,"type":53},"2017-07-24",{"date":544,"type":21},"2027-07-23",{"name":546,"class":102},"Blood Cancer United"]